OBJECTIVES: Coronary heart disease (CHD) remains the leading cause of death in China, requiring long-term treatment. Angina pectoris is the most common symptom of CHD. Because of fewer side effects and its application in multiple pathological link in CHD, Chinese patent medicine continue to increase its importance in the long-term treatment of angina pectoris. This study aimed to estimate the cost-effectiveness of Suxiao jiuxin pill, Shexiang baoxin pill, Tongxinluo capsule and Compound Danshen dropping pill in the treatment of angina pectoris, to provide reference for reasonable clinical prescription. METHODS: A decision-analytic model was developed to estimate the cost-effectiveness of Suxiao jiuxin pill, Shexiang baoxin pill, Tongxinluo capsule and Compound Danshen dropping pill from the perspective of the whole society with a time horizon of 4 weeks. In the model, outcome on effectiveness was based on quantitative synthetic of Meta analysis.And cost data was mainly based on the published data and in combination with China's practical situation. Uncertainty was investigated with probabilistic sensitivity analysis, and the expected value of efficient, period of treatment, drug prices and average daily dose were also calculated. RESULTS: The effective rates of Suxiao jiuxin pill,Shexiang baoxin pill,Tongxinluo capsule and Compound Danshen dropping pill were 89.67%, 87.11%, 85.13%, 83.71%, respectively; total costs were $62.31,$64.21,$100.29,$70.08, respectively.Sensitivity analysis suggested the robustness of the results. CONCLUSIONS: Results of the model indicate that Suxiao jiuxin pill appears to be the most cost-effective.The availability of more high-quality clinical data would allow a better adaptation of the model . Future research could be focused on this.